Olaparib (PARP inhibitor)
Treatment for Pancreatic Cancer
Typical Dosage: 300 mg orally twice daily
Effectiveness
70%
Safety Score
50%
Clinical Trials
20
Participants
500
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
300 mg orally twice daily
Time to Effect
Weeks
Treatment Duration
Long-term maintenance, until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
4(Treat 4 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200,000
Monitoring:$8,000
Side Effect Mgmt:$10,000
Total Annual:$218,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.25
Comparison vs Placebo
Cost Difference
+$200,000/year
More expensive
QALY Difference
+0.25 QALYs
Better outcomes
Dominance
No dominance
Olaparib (PARP inhibitor) Outcomes
for Pancreatic Cancer
Efficacy Outcomes
Overall Effectiveness
+70%
Common Side Effects
Nausea
+50%
Fatigue
+40%
Anemia (Grade 3/4)
+24%
Vomiting
+24%
Active Clinical Trials
12 active trials recruiting for Olaparib (PARP inhibitor) in Pancreatic Cancer
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
NCT06130254RECRUITINGPHASE1
52 participants
INTERVENTIONAL
Houston, United States
Started: Jan 30, 2024
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
NCT05093231RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Cambridge, United Kingdom +12 more
Started: Feb 26, 2025
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942RECRUITINGPHASE1
220 participants
INTERVENTIONAL
Goodyear, United States +17 more
Started: Aug 13, 2024
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT03682289RECRUITINGPHASE2
89 participants
INTERVENTIONAL
Duarte, United States +2 more
Started: Jan 17, 2019
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04858334RECRUITINGPHASE2
152 participants
INTERVENTIONAL
Anchorage, United States +452 more
Started: Jun 22, 2021
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
NCT04005690RECRUITINGEARLY_PHASE1
90 participants
INTERVENTIONAL
Portland, United States
Started: Aug 1, 2019
Study of LP-184 in Patients With Advanced Solid Tumors
NCT05933265RECRUITINGPHASE1, PHASE2
175 participants
INTERVENTIONAL
Springdale, United States +8 more
Started: Jun 9, 2023
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
NCT03851614ACTIVE NOT RECRUITINGPHASE2
90 participants
INTERVENTIONAL
Toronto, Canada
Started: Apr 8, 2019
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
NCT05411094RECRUITINGPHASE1
18 participants
INTERVENTIONAL
Irvine, United States +10 more
Started: May 22, 2023
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT02498613ACTIVE NOT RECRUITINGPHASE2
122 participants
INTERVENTIONAL
La Jolla, United States +15 more
Started: Aug 31, 2016
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
NCT04548752ACTIVE NOT RECRUITINGPHASE2
88 participants
INTERVENTIONAL
Anchorage, United States +535 more
Started: Feb 22, 2021
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
NCT06630325ACTIVE NOT RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Portland, United States
Started: Jun 24, 2025
Completed Clinical Trials
4 completed trials for Olaparib (PARP inhibitor) in Pancreatic Cancer
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
NCT00515866COMPLETEDPHASE1
68 participants
INTERVENTIONAL
New York, United States +3 more
Started: Aug 1, 2007
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
NCT02677038COMPLETEDPHASE2
24 participants
INTERVENTIONAL
Houston, United States
Started: Nov 11, 2016
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
NCT01078662COMPLETEDPHASE2
298 participants
INTERVENTIONAL
West Hollywood, United States +13 more
Started: Feb 21, 2010
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
NCT02184195COMPLETEDPHASE3
154 participants
INTERVENTIONAL
Gilbert, United States +102 more
Started: Dec 16, 2014